Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 20/20 | 0.68 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.68 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.68 |
| ▸ | PDE1A | P54750 | 8/20 | 0.66 |
| ▸ | PDE1B | Q01064 | 8/20 | 0.66 |
| ▸ | PDE1C | Q14123 | 8/20 | 0.66 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | PDE2A | O00408 | 1/20 | 0.55 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.55 |
| ▸ | ABCC5 | O15440 | 1/20 | 0.55 |
| ▸ | PDE6D | O43924 | 1/20 | 0.55 |
| ▸ | PDE8A | O60658 | 1/20 | 0.55 |
| ▸ | PDE9A | O76083 | 1/20 | 0.55 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.55 |
| ▸ | PDE6A | P16499 | 1/20 | 0.55 |
| ▸ | PDE6G | P18545 | 1/20 | 0.55 |
| ▸ | PDE4A | P27815 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3840535 | 0.94 | PDE5A (0.68) | PDE5APDE3BPDE3APDE1APDE1B | |
| SCHEMBL7168287 | 0.91 | PDE5A (0.67) | PDE5APDE3BPDE3APDE1APDE1B | |
| SCHEMBL3841161 | 0.89 | PDE5A (0.64) | PDE5APDE3BPDE3APDE1APDE1B | |
| SCHEMBL7168383 | 0.88 | PDE5A (0.66) | PDE5APDE3BPDE3APDE1APDE1B | |
| SCHEMBL9277180 | 0.88 | PDE5A (0.64) | PDE5APDE3BPDE3APDE1APDE1B | |
| SCHEMBL7167327 | 0.87 | PDE5A (0.66) | PDE5APDE3BPDE3APDE1APDE1B | |
| SCHEMBL6642736 | 0.82 | PDE5A (0.76) | PDE5APDE3BPDE3APDE1APDE1B | |
| SCHEMBL6646085 | 0.82 | PDE5A (0.75) | PDE5APDE3BPDE3APDE1APDE1B | |
| SCHEMBL3840503 | 0.81 | PDE5A (0.72) | PDE5APDE3BPDE3APDE1APDE1B | |
| SCHEMBL3026814 | 0.81 | PDE5A (0.63) | PDE5APDE3BPDE3APDE1APDE1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1365806-A2 | USE OF NO ACTTIVATORS FOR TREATMENT AND PREVENTION OF GASTROINTESTINAL DISORDERS | JOHNS HOPKINS UNIVERSITY (US) | 2003-12-03 | — | — | EP | claimed |
| EP-0793498-B1 | BICYCLIC HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF IMPOTENCE | PFIZER LTD (GB) | 2002-12-11 | — | — | EP | claimed |
| US-20020128171-A1 | Methods for prevention and treatment of gastrointestinal disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-09-12 | — | — | US | claimed |
| WO-2001078781-A9 | METHODS FOR PREVENTION AND TREATMENT OF GASTROINTESTINAL DISORDERS | UNIV JOHNS HOPKINS (US) | 2002-07-25 | — | — | WO | claimed |
| WO-2001078781-A2 | METHODS FOR PREVENTION AND TREATMENT OF GASTROINTESTINAL DISORDERS | JOHNS HOPKINS UNIVERSITY (US) | 2001-10-25 | — | — | WO | claimed |
| US-6225315-B1 | ADMINISTERING A CGMP PDE INHIBITOR. | PFIZER INC | 2001-05-01 | — | — | US | claimed |
| EP-1022026-A2 | Pharmaceutical compositions for treating nitrate-induced tolerance | Pfizer Limited (GB) | 2000-07-26 | — | — | EP | claimed |
| EP-0628032-B1 | QUINAZOLINONE ANTIANGINAL AGENTS | PFIZER LTD (GB) | 1998-05-13 | — | — | EP | claimed |
| EP-0793498-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF IMPOTENCE | Pfizer Limited (GB) | 1997-09-10 | — | — | EP | claimed |
| JP-2525126-B2 | — | PFIZER | 1996-08-14 | — | — | JP | claimed |
| WO-1996016657-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF IMPOTENCE | PFIZER LIMITED (GB) | 1996-06-06 | — | — | WO | claimed |
| US-5482941-A | Quinazolinone antianginal agents | PFIZER INC. (US) | 1996-01-09 | — | — | US | claimed |
| EP-0628032-A1 | QUINAZOLINONE ANTIANGINAL AGENTS | Pfizer Limited (GB) | 1994-12-14 | — | — | EP | claimed |
| WO-1993012095-A1 | QUINAZOLINONE ANTIANGINAL AGENTS | PFIZER LIMITED (GB) | 1993-06-24 | — | — | WO | claimed |
| EP-1331950-B1 | EX VIVO METHODS AND COMPOSITIONS FOR NUCLEIC ACID DELIVERY | UNIV JOHNS HOPKINS (US) | 2009-10-14 | — | — | EP | disclosed |
| US-20070197560-A1 | cGMP PDE 5 inhibitors for inhalation in the treatment of sexual dysfunction | NAEF RETO | 2007-08-23 | — | — | US | disclosed |
| US-6992070-B2 | Methods and compositions for nucleic acid delivery | THE JOHNS HOPKINS UNIVERSITY (US) | 2006-01-31 | — | — | US | disclosed |
| US-5482941-A | Quinazolinone antianginal agents | PFIZER INC. (US) | 1996-01-09 | — | — | US | disclosed |
| EP-0628032-A1 | QUINAZOLINONE ANTIANGINAL AGENTS | Pfizer Limited (GB) | 1994-12-14 | — | — | EP | disclosed |
| WO-1993012095-A1 | QUINAZOLINONE ANTIANGINAL AGENTS | PFIZER LIMITED (GB) | 1993-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128171-A1 | Methods for prevention and treatment of gastrointestinal disorders | VIP, GIPR, IAPP | PDE5A 302/4885PDE3B 153/4885PDE3A 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.